Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis
Background: Several studies proposed the use of positron emission tomography (PET) with Prostate-Specific Membrane Antigen (PSMA)-targeting radiopharmaceuticals in hepatocellular carcinoma (HCC). Our aim is to calculate the detection rate (DR) of this examination in HCC with a meta-analysis. Methods...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/15/11/1368 |
| _version_ | 1827645800747892736 |
|---|---|
| author | Alessio Rizzo Manuela Racca Domenico Albano Francesco Dondi Francesco Bertagna Salvatore Annunziata Giorgio Treglia |
| author_facet | Alessio Rizzo Manuela Racca Domenico Albano Francesco Dondi Francesco Bertagna Salvatore Annunziata Giorgio Treglia |
| author_sort | Alessio Rizzo |
| collection | DOAJ |
| description | Background: Several studies proposed the use of positron emission tomography (PET) with Prostate-Specific Membrane Antigen (PSMA)-targeting radiopharmaceuticals in hepatocellular carcinoma (HCC). Our aim is to calculate the detection rate (DR) of this examination in HCC with a meta-analysis. Methods: A comprehensive literature search of studies on the DR of PET/CT or PET/MRI with PSMA-targeting radiopharmaceuticals in HCC was performed. Original articles evaluating these imaging examinations both in newly diagnosed HCC patients and HCC patients with disease relapse were included. Pooled DR including 95% confidence intervals (95% CI) was calculated. Statistical heterogeneity was also assessed using the I<sup>2</sup> test. Results: The meta-analysis of six selected studies (126 patients) provided a DR of 85.9% for PET imaging with PSMA-targeting radiopharmaceuticals in the diagnosis of HCC. Moderate statistical heterogeneity among the included studies was found (I<sup>2</sup> = 56%). Conclusions: The quantitative data provided demonstrate the high DR of PET/CT or PET/MRI with PSMA-targeting radiopharmaceuticals for HCC lesion detection. However, more studies are needed to confirm the promising role of PSMA-targeted PET in HCC. |
| first_indexed | 2024-03-09T18:45:16Z |
| format | Article |
| id | doaj.art-a3c4a12920604f5fb28a0b383c560605 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-09T18:45:16Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-a3c4a12920604f5fb28a0b383c5606052023-11-24T06:18:50ZengMDPI AGPharmaceuticals1424-82472022-11-011511136810.3390/ph15111368Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-AnalysisAlessio Rizzo0Manuela Racca1Domenico Albano2Francesco Dondi3Francesco Bertagna4Salvatore Annunziata5Giorgio Treglia6Department of Nuclear Medicine, Candiolo Cancer Institute, FPO—IRCCS, 10060 Turin, ItalyDepartment of Nuclear Medicine, Candiolo Cancer Institute, FPO—IRCCS, 10060 Turin, ItalyDivision of Nuclear Medicine, Università Degli Studi di Brescia and ASST Spedali Civili di Brescia, 25123 Brescia, ItalyDivision of Nuclear Medicine, Università Degli Studi di Brescia and ASST Spedali Civili di Brescia, 25123 Brescia, ItalyDivision of Nuclear Medicine, Università Degli Studi di Brescia and ASST Spedali Civili di Brescia, 25123 Brescia, ItalyUnità di Medicina Nucleare, TracerGLab, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, ItalyClinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6501 Bellinzona, SwitzerlandBackground: Several studies proposed the use of positron emission tomography (PET) with Prostate-Specific Membrane Antigen (PSMA)-targeting radiopharmaceuticals in hepatocellular carcinoma (HCC). Our aim is to calculate the detection rate (DR) of this examination in HCC with a meta-analysis. Methods: A comprehensive literature search of studies on the DR of PET/CT or PET/MRI with PSMA-targeting radiopharmaceuticals in HCC was performed. Original articles evaluating these imaging examinations both in newly diagnosed HCC patients and HCC patients with disease relapse were included. Pooled DR including 95% confidence intervals (95% CI) was calculated. Statistical heterogeneity was also assessed using the I<sup>2</sup> test. Results: The meta-analysis of six selected studies (126 patients) provided a DR of 85.9% for PET imaging with PSMA-targeting radiopharmaceuticals in the diagnosis of HCC. Moderate statistical heterogeneity among the included studies was found (I<sup>2</sup> = 56%). Conclusions: The quantitative data provided demonstrate the high DR of PET/CT or PET/MRI with PSMA-targeting radiopharmaceuticals for HCC lesion detection. However, more studies are needed to confirm the promising role of PSMA-targeted PET in HCC.https://www.mdpi.com/1424-8247/15/11/1368PSMAPETnuclear medicineliverhepatocellular carcinomaoncology |
| spellingShingle | Alessio Rizzo Manuela Racca Domenico Albano Francesco Dondi Francesco Bertagna Salvatore Annunziata Giorgio Treglia Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis Pharmaceuticals PSMA PET nuclear medicine liver hepatocellular carcinoma oncology |
| title | Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis |
| title_full | Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis |
| title_fullStr | Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis |
| title_full_unstemmed | Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis |
| title_short | Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis |
| title_sort | can psma targeting radiopharmaceuticals be useful for detecting hepatocellular carcinoma using positron emission tomography an updated systematic review and meta analysis |
| topic | PSMA PET nuclear medicine liver hepatocellular carcinoma oncology |
| url | https://www.mdpi.com/1424-8247/15/11/1368 |
| work_keys_str_mv | AT alessiorizzo canpsmatargetingradiopharmaceuticalsbeusefulfordetectinghepatocellularcarcinomausingpositronemissiontomographyanupdatedsystematicreviewandmetaanalysis AT manuelaracca canpsmatargetingradiopharmaceuticalsbeusefulfordetectinghepatocellularcarcinomausingpositronemissiontomographyanupdatedsystematicreviewandmetaanalysis AT domenicoalbano canpsmatargetingradiopharmaceuticalsbeusefulfordetectinghepatocellularcarcinomausingpositronemissiontomographyanupdatedsystematicreviewandmetaanalysis AT francescodondi canpsmatargetingradiopharmaceuticalsbeusefulfordetectinghepatocellularcarcinomausingpositronemissiontomographyanupdatedsystematicreviewandmetaanalysis AT francescobertagna canpsmatargetingradiopharmaceuticalsbeusefulfordetectinghepatocellularcarcinomausingpositronemissiontomographyanupdatedsystematicreviewandmetaanalysis AT salvatoreannunziata canpsmatargetingradiopharmaceuticalsbeusefulfordetectinghepatocellularcarcinomausingpositronemissiontomographyanupdatedsystematicreviewandmetaanalysis AT giorgiotreglia canpsmatargetingradiopharmaceuticalsbeusefulfordetectinghepatocellularcarcinomausingpositronemissiontomographyanupdatedsystematicreviewandmetaanalysis |